Literature DB >> 1376595

Antiretroviral therapy: reverse transcriptase inhibition.

K J Connolly1, S M Hammer.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1376595      PMCID： PMC188341          DOI： 10.1128/AAC.36.2.245

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  82 in total

1.  Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection.

Authors:  J M Pluda; R Yarchoan; P D Smith; N McAtee; L E Shay; D Oette; M Maha; S M Wahl; C E Myers; S Broder
Journal:  Blood       Date:  1990-08-01       Impact factor: 22.113

Review 2.  Zidovudine update: 1990.

Authors:  G D Morse; J L Lechner; J A Santora; S L Rozek
Journal:  DICP       Date:  1990 Jul-Aug

3.  Failure of zidovudine prophylaxis after accidental exposure to HIV-1.

Authors:  J M Lange; C A Boucher; C E Hollak; E H Wiltink; P Reiss; E A van Royen; M Roos; S A Danner; J Goudsmit
Journal:  N Engl J Med       Date:  1990-05-10       Impact factor: 91.245

4.  Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.

Authors:  E G Sandstrom; J C Kaplan; R E Byington; M S Hirsch
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

5.  Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; J P Sommadossi; V Saalmann; D L Cannon; M Y Xie; G C Hart; G A Smith; E F Hahn
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro.

Authors:  T Shirasaka; K Murakami; H Ford; J A Kelley; H Yoshioka; E Kojima; S Aoki; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

7.  In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.

Authors:  R Yarchoan; H Mitsuya; R V Thomas; J M Pluda; N R Hartman; C F Perno; K S Marczyk; J P Allain; D G Johns; S Broder
Journal:  Science       Date:  1989-07-28       Impact factor: 47.728

Review 8.  Salvage therapy for zidovudine-intolerant HIV-infected patients with alternating and intermittent regimens of zidovudine and dideoxycytidine.

Authors:  S A Bozzette; D D Richman
Journal:  Am J Med       Date:  1990-05-21       Impact factor: 4.965

9.  Recombinant human erythropoietin for patients with AIDS treated with zidovudine.

Authors:  M Fischl; J E Galpin; J D Levine; J E Groopman; D H Henry; P Kennedy; S Miles; W Robbins; B Starrett; R Zalusky
Journal:  N Engl J Med       Date:  1990-05-24       Impact factor: 91.245

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205
View more
  7 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 2.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

3.  Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine.

Authors:  P Harvie; A Désormeaux; M C Bergeron; M Tremblay; D Beauchamp; L Poulin; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase.

Authors:  G Borkow; J Barnard; T M Nguyen; A Belmonte; M A Wainberg; M A Parniak
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 5.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

Authors:  R E Rose; Y F Gong; J A Greytok; C M Bechtold; B J Terry; B S Robinson; M Alam; R J Colonno; P F Lin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

7.  Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages.

Authors:  R Geleziunas; E J Arts; F Boulerice; H Goldman; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.